Next Theme
01 / 02

Through independent research and development, license-in and business development, we are committed to the exploration of innovative drugs for autoimmune diseases and to fulfill unmet medical needs and to improve the quality of human life.

R&D and Product Pipeline
QY201, independently developed by E-nitiate with global patents, is undergoing phase I clinical trial for atopic dermatitis. Other pipelines, such as QY101, QY211, QY301, are also about to enter the clinical stage.